| 000 | 01762 a2200505 4500 | ||
|---|---|---|---|
| 005 | 20250517103733.0 | ||
| 264 | 0 | _c20170606 | |
| 008 | 201706s 0 0 eng d | ||
| 022 | _a1432-0843 | ||
| 024 | 7 |
_a10.1007/s00280-016-3098-3 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aChow, Laura Q M | |
| 245 | 0 | 0 |
_aLack of pharmacokinetic drug-drug interaction between ramucirumab and paclitaxel in a phase II study of patients with advanced malignant solid tumors. _h[electronic resource] |
| 260 |
_bCancer chemotherapy and pharmacology _cAug 2016 |
||
| 300 |
_a433-41 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 | _aAged, 80 and over |
| 650 | 0 | 4 |
_aAntibodies, Monoclonal _xadministration & dosage |
| 650 | 0 | 4 | _aAntibodies, Monoclonal, Humanized |
| 650 | 0 | 4 |
_aAntineoplastic Combined Chemotherapy Protocols _xadministration & dosage |
| 650 | 0 | 4 | _aArea Under Curve |
| 650 | 0 | 4 | _aDrug Interactions |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aIncidence |
| 650 | 0 | 4 | _aLeast-Squares Analysis |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aNeoplasms _xdrug therapy |
| 650 | 0 | 4 |
_aPaclitaxel _xadministration & dosage |
| 650 | 0 | 4 | _aYoung Adult |
| 650 | 0 | 4 | _aRamucirumab |
| 700 | 1 | _aSmith, David C | |
| 700 | 1 | _aTan, Antoinette R | |
| 700 | 1 | _aDenlinger, Crystal S | |
| 700 | 1 | _aWang, Ding | |
| 700 | 1 | _aShepard, Dale R | |
| 700 | 1 | _aChaudhary, Archana | |
| 700 | 1 | _aLin, Yong | |
| 700 | 1 | _aGao, Ling | |
| 773 | 0 |
_tCancer chemotherapy and pharmacology _gvol. 78 _gno. 2 _gp. 433-41 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1007/s00280-016-3098-3 _zAvailable from publisher's website |
| 999 |
_c26192286 _d26192286 |
||